Miguel Martín
Miguel Martín is the founder of the Spanish breast cancer group GEICAM and a leader of adjuvant chemotherapy trials.
Miguel Martín founded and chairs GEICAM, Spain's breast cancer research group, and led trials of adjuvant docetaxel-based regimens and CDK4/6 inhibitors including participation in PALLAS and monarchE.
| Title | Journal | Year |
|---|---|---|
| Adjuvant docetaxel for node-positive breast cancer (BCIRG 001) | NEJM | 2005 |
Ribociclib is a second adjuvant CDK4/6 option, and the only one with data in node-negative stage II disease. Roughly 3 in 100 patients avoid a relapse or death at three years, so the decision depends heavily on individual risk, tolerance of a three-year oral drug, and cost. Whether the benefit persists after treatment ends, as it did with abemaciclib, needs longer follow-up.
Women with hormone-receptor-positive, HER2-negative breast cancer that has spread to lymph nodes and has other high-risk features can now be offered two years of abemaciclib alongside their hormone therapy, with a durable reduction in relapse. It does not apply to node-negative or low-risk disease, and the diarrhoea and cost are real trade-offs to discuss.
Pages like this
not linked directly; found by shared links- PersonSara López-Tarruella
Shares Hospital General Universitario Gregorio Marañón, GEICAM Spanish Breast Cancer Group, Triple-negative breast cancer (TNBC).
- InstitutionAustrian Breast & Colorectal Cancer Study Group
Shares PALLAS & PENELOPE-B, Palbociclib, HR-positive / HER2-negative breast cancer.
- InstitutionSOLTI Cancer Research Group
Shares GEICAM Spanish Breast Cancer Group, Palbociclib, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- TrialNATALEE
Shares monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer, NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer, HR-positive / HER2-negative breast cancer.
- PersonSeock-Ah Im
Shares NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer, Palbociclib, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PairingCDK4/6 inhibitor + endocrine therapy
Shares Abemaciclib, Palbociclib, HR-positive / HER2-negative breast cancer.
- IdeaCDK4-selective inhibitors as the new first-line backbone
Shares Abemaciclib, Palbociclib, HR-positive / HER2-negative breast cancer.
- PersonAngela DeMichele
Shares Palbociclib, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.